InflaRx N.V. (IFRX) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Immuneering (IMRX) over the past year, gaining 13.0% versus a loss of 36.8%. Over five years, IFRX leads with a -36.8% price change compared with -84.5% for IMRX. Immuneering is the larger company by market cap ($241.6 million vs $219.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | IMRX |
|---|---|---|
| Share price | $1.49 | $3.74 |
| Market cap | $219.58M | $241.64M |
| 1-day change | -4.49% | -3.24% |
| YTD return | +54.46% | -41.34% |
| 1-year return | +13.04% | -36.82% |
| 5-year return | -36.84% | -84.47% |
| EPS (TTM) | $-0.58 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $8.48 |
| 52-week low | $0.798 | $3.60 |
| Distance from 52-week high | -49.47% | -55.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +414.09% | +359.71% |
| Average volume | 794.10K | 694.54K |
| Shares outstanding | 147.37M | 64.70M |
| Employees | 65 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed IMRX by 49.9 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
IFRX vs IMRX FAQ
Which is bigger, InflaRx N.V. or Immuneering?
Immuneering (IMRX) is larger, with a market capitalization of $241.64M compared with $219.58M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or IMRX?
IFRX returned +13.04% over the past 12 months, compared with -36.82% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.